Nilotinib: from Animal-based Studies to Clinical Investigation in Alzheimer's Disease Patients

Overview

Journal Neural Regen Res

Date 2022 Oct 7

PMID 36204843

Authors

Annalisa Nobili

Marcello DAmelio

Maria Teresa Viscomi

Affiliations

Soon will be listed here.

Citing Articles

Autophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer's disease.

Mancano A, Pina J, Froes B, Sciani J Front Mol Biosci. 2024; 11:1490275.

PMID: 39544403 PMC: 11560772. DOI: 10.3389/fmolb.2024.1490275.

Nilotinib as a Prospective Treatment for Alzheimer's Disease: Effect on Proteins Involved in Neurodegeneration and Neuronal Homeostasis.

Srivastava A, Renna H, Johnson M, Sheehan K, Ahmed S, Palaia T Life (Basel). 2024; 14(10).

PMID: 39459541 PMC: 11509617. DOI: 10.3390/life14101241.

Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.

IsHak W, Meyer A, Freire L, Totlani J, Murphy N, Renteria S Innov Clin Neurosci. 2024; 21(7-9):27-47.

PMID: 39329027 PMC: 11424068.

Loss of glycine receptors in the nucleus accumbens and ethanol reward in an Alzheimer´s Disease mouse model.

Armijo-Weingart L, San Martin L, Gallegos S, Araya A, Konar-Nie M, Fernandez-Perez E Prog Neurobiol. 2024; 237:102616.

PMID: 38723884 PMC: 11163974. DOI: 10.1016/j.pneurobio.2024.102616.

Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation.

Yan C, Grabowska M, Dickson A, Li B, Wen Z, Roden D NPJ Digit Med. 2024; 7(1):46.

PMID: 38409350 PMC: 10897392. DOI: 10.1038/s41746-024-01038-3.

References

Tondo G, Boccalini C, Caminiti S, Presotto L, Filippi M, Magnani G . Brain Metabolism and Microglia Activation in Mild Cognitive Impairment: A Combined [18F]FDG and [11C]-(R)-PK11195 PET Study. J Alzheimers Dis. 2021; 80(1):433-445. DOI: 10.3233/JAD-201351. View

Adlimoghaddam A, Odero G, Glazner G, Turner R, Albensi B . Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimer's Disease. Aging Dis. 2021; 12(2):441-465. PMC: 7990369. DOI: 10.14336/AD.2020.0910. View

Nobili A, Latagliata E, Viscomi M, Cavallucci V, Cutuli D, Giacovazzo G . Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease. Nat Commun. 2017; 8:14727. PMC: 5382255. DOI: 10.1038/ncomms14727. View

Sala A, Caminiti S, Presotto L, Pilotto A, Liguori C, Chiaravalloti A . In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimer's disease phases. Alzheimers Res Ther. 2021; 13(1):187. PMC: 8588696. DOI: 10.1186/s13195-021-00925-1. View

Turner R, Hebron M, Lawler A, Mundel E, Yusuf N, Starr J . Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease. Ann Neurol. 2020; 88(1):183-194. PMC: 7383852. DOI: 10.1002/ana.25775. View

Hebron M, Lonskaya I, Moussa C . Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. Hum Mol Genet. 2013; 22(16):3315-28. PMC: 3723316. DOI: 10.1093/hmg/ddt192. View

La Barbera L, Vedele F, Nobili A, Krashia P, Spoleti E, Latagliata E . Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease. Prog Neurobiol. 2021; 202:102031. DOI: 10.1016/j.pneurobio.2021.102031. View

Lonskaya I, Hebron M, Selby S, Turner R, Moussa C . Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimer's disease models. Neuroscience. 2015; 304:316-27. DOI: 10.1016/j.neuroscience.2015.07.070. View

Serra L, DAmelio M, Di Domenico C, Dipasquale O, Marra C, Mercuri N . In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease. Neurobiol Aging. 2018; 72:72-82. DOI: 10.1016/j.neurobiolaging.2018.08.012. View

10.

Krashia P, Nobili A, DAmelio M . Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease. Front Mol Neurosci. 2019; 12:123. PMC: 6534044. DOI: 10.3389/fnmol.2019.00123. View

11.

Lonskaya I, Hebron M, Desforges N, Franjie A, Moussa C . Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med. 2013; 5(8):1247-62. PMC: 3944464. DOI: 10.1002/emmm.201302771. View

12.

De Marco M, Venneri A . Volume and Connectivity of the Ventral Tegmental Area are Linked to Neurocognitive Signatures of Alzheimer's Disease in Humans. J Alzheimers Dis. 2018; 63(1):167-180. DOI: 10.3233/JAD-171018. View